To the Editor,

We congratulate Grigoras et al. ([@ref1]) on their comprehensive and perceptive review titled "Perivascular adipose tissue in cardiovascular diseases-an update". However, some additional comments may be of interest.

Grigoras et al. ([@ref1]) report that the perivascular adipose tissue (PVAT) differs in properties depending on its anatomical location. Other authors have also reported similar findings ([@ref2]). These properties, together with the anatomical structural variations, may eventually facilitate the use of a specific treatment for a specific blood vessel, in addition to the usual general measures. In this context, we also need to consider that blood vessels, at different locations, may have different receptor distributions ([@ref3]).

An abnormal PVAT is probably associated with abnormal peri-organ and intra-organ fat at other sites, and this may indirectly increase the risk of vascular events ([@ref4]-[@ref6]). Grigoras et al. ([@ref1]) also mention the potential role of various drugs on PVAT. This will be an area of considerable interest for further research ([@ref1],[@ref6]).

Grigoras et al. ([@ref1]) discuss a carotid model in the context of PVAT. Indeed, other authors have reported links between the PVAT and internal carotid arteries (ICA) stenosis ([@ref7]). Furthermore, the pericarotid fat density has been associated with an increased risk of stroke and transient ischemic attack in patients with unilateral ICA stenosis ≥50%--99% ([@ref8]).

The review by Grigoras et al. ([@ref1]) made a considerable contribution to the field discussed above.
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